Aspire Biopharma Q2 FY26 net loss narrows to $1.27 million; revenue rises to $63,104

ASBP•2026-08-13

Six-month loss improves year over year

Six-month net loss narrowed to USD 4.49 million from USD 17.92 million; operating loss improved to USD 4.32 million from USD 16.36 million.

Acquisition of Dura Drive Control Systems completed

Completed acquisition of Dura Drive Control Systems on Aug. 10, 2026, targeting increased revenue, earnings, and cash flow from automotive control systems.

Q2 results show narrower net loss but wider operating loss

Aspire Biopharma posted Q2 net loss of USD 1.27 million, narrowing from USD 1.98 million a year earlier.

Revenue was USD 63,104, versus no revenue a year earlier; gross margin was negative USD 30,086 on USD 42,372 inventory write-off.

Operating loss widened to USD 2.68 million from USD 799,890, as sales and marketing climbed to USD 1.22 million from .

Sources

Aspire Biopharma Q2 FY26 net loss narrows to $1.27 million; revenue rises to $63,104

Sec

Aspire Biopharma Q2 FY26 net loss narrows to $1.27 million; revenue rises to $63,104

Six-month loss improves year over year

Acquisition of Dura Drive Control Systems completed

Q2 results show narrower net loss but wider operating loss

Related News

Ibotta director Thomas D. Lehrman disposes of common shares worth $1.53 million

Duke Energy restores 85% of Greater Cincinnati outages; crews on track to restore nearly all remaining outages Thursday

ITHAX Acquisition III Q2 FY26 net income rises to $1.96 million; six-month profit increases to $3.75 million

Sources

Aspire Biopharma Q2 FY26 net loss narrows to $1.27 million; revenue rises to $63,104

One Liberty Properties - May Offer Securities Up To $250 Million

Mativ to present at Seaport Research Partners investor conference